JP2018506964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506964A5 JP2018506964A5 JP2017535814A JP2017535814A JP2018506964A5 JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5 JP 2017535814 A JP2017535814 A JP 2017535814A JP 2017535814 A JP2017535814 A JP 2017535814A JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- cell
- heavy chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000004671 cell-free system Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 102000004195 Isomerases Human genes 0.000 claims description 4
- 108090000769 Isomerases Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 3
- 206010057249 Phagocytosis Diseases 0.000 claims description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000008782 phagocytosis Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- -1 E or D Chemical class 0.000 claims description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 102000044459 human CD47 Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 101150036449 SIRPA gene Proteins 0.000 claims 1
- 238000010276 construction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098291P | 2014-12-30 | 2014-12-30 | |
| US62/098,291 | 2014-12-30 | ||
| PCT/US2015/067642 WO2016109415A1 (en) | 2014-12-30 | 2015-12-28 | Anti-cd47 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Division JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506964A JP2018506964A (ja) | 2018-03-15 |
| JP2018506964A5 true JP2018506964A5 (enExample) | 2019-05-23 |
| JP6850255B2 JP6850255B2 (ja) | 2021-03-31 |
Family
ID=56284963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535814A Expired - Fee Related JP6850255B2 (ja) | 2014-12-30 | 2015-12-28 | 抗−ｃｄ４７抗体及びその使用 |
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10870699B2 (enExample) |
| EP (1) | EP3240569A4 (enExample) |
| JP (2) | JP6850255B2 (enExample) |
| KR (1) | KR102489471B1 (enExample) |
| CN (1) | CN107530421B (enExample) |
| AU (1) | AU2015374301B2 (enExample) |
| BR (1) | BR112017014258A2 (enExample) |
| CA (1) | CA2972604C (enExample) |
| CL (1) | CL2017001736A1 (enExample) |
| CO (1) | CO2017007673A2 (enExample) |
| EA (1) | EA037654B1 (enExample) |
| EC (1) | ECSP17041865A (enExample) |
| HK (1) | HK1245154A1 (enExample) |
| MX (1) | MX391051B (enExample) |
| SG (2) | SG11201705310TA (enExample) |
| WO (1) | WO2016109415A1 (enExample) |
| ZA (1) | ZA201704467B (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| EP3481862A4 (en) * | 2016-07-06 | 2020-08-12 | Celgene Corporation | LOW IMMUNOGENIC ANTIBODIES AND USES THEREOF |
| US11498977B2 (en) | 2016-09-29 | 2022-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| EP3411071A4 (en) | 2016-10-20 | 2019-08-28 | I-Mab | NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF |
| US11779631B2 (en) | 2016-11-03 | 2023-10-10 | Pfizer Inc. | CD47 blockade therapy by HDAC inhibitors |
| US11352425B2 (en) * | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| CA3043652A1 (en) | 2016-11-18 | 2018-05-24 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
| KR102607101B1 (ko) * | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
| WO2018152033A1 (en) * | 2017-02-14 | 2018-08-23 | Promab Biotechnologies, Inc. | Cd47-car-t cells |
| KR20190133198A (ko) * | 2017-03-27 | 2019-12-02 | 셀진 코포레이션 | 면역원성의 감소를 위한 방법 및 조성물 |
| KR102808275B1 (ko) | 2017-04-14 | 2025-05-20 | 탈락 테라퓨틱스, 인크. | 면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법 |
| US11401329B2 (en) * | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| EP4435008A2 (en) | 2017-08-18 | 2024-09-25 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| EP3541941A4 (en) * | 2017-11-10 | 2019-12-25 | I-Mab Biopharma US Limited | FUSION PROTEINS CONTAINING ANTI-CD47 ANTIBODIES AND CYTOKINES |
| TWI831759B (zh) | 2017-12-01 | 2024-02-11 | 美商思進公司 | Cd47抗體及其用於治療癌症之用途 |
| EA202091364A1 (ru) | 2017-12-04 | 2020-10-13 | Бейджин Ханми Фармасьютикал Ко., Лтд. | Анти-pd-l1/анти-cd47 биспецифическое антитело с подобной природному антителу структурой и в форме гетеродимера и способ его получения |
| AU2019212674A1 (en) * | 2018-01-24 | 2020-09-03 | Nanjing Legend Biotech Co., Ltd. | Anti-CD47 antibodies that do not cause significant red blood cell agglutination |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| WO2019241732A1 (en) | 2018-06-15 | 2019-12-19 | Accurus Biosciences, Inc. | Blocking antibodies against cd47 and methods of use thereof |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| CN110872348B (zh) * | 2018-09-03 | 2021-09-03 | 长春金赛药业有限责任公司 | 人源化抗cd47单克隆抗体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3826676A4 (en) * | 2018-10-31 | 2022-05-04 | I-Mab Biopharma US Limited | NOVEL CD47 ANTIBODIES AND METHODS OF USE THEREOF |
| JP2022523543A (ja) | 2019-03-06 | 2022-04-25 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 二機能性融合タンパク質及びその医薬的使用 |
| TW202104260A (zh) | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| CN112516301B (zh) * | 2019-09-17 | 2025-03-18 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体的液体制剂及其制备方法 |
| KR102902719B1 (ko) | 2019-10-18 | 2025-12-24 | 포티 세븐, 엘엘씨 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| AU2020372522B2 (en) * | 2019-10-25 | 2024-08-15 | WuXi Biologics Ireland Limited | Novel anti-CD47 antibodies and uses thereof |
| CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| EP4445902A3 (en) | 2019-12-24 | 2024-12-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| US11920136B2 (en) | 2020-02-28 | 2024-03-05 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| US20230220075A1 (en) | 2020-06-22 | 2023-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| EP4190813A4 (en) * | 2020-07-31 | 2025-02-12 | Bio-Thera Solutions, Ltd. | CD47 ANTIBODIES AND THEIR APPLICATION |
| JP2023544254A (ja) * | 2020-09-14 | 2023-10-23 | ストロ バイオファーマ， インコーポレイテッド | 無細胞タンパク質合成系を用いた抗体の大規模産生方法 |
| JP2023545983A (ja) | 2020-10-07 | 2023-11-01 | セルジーン コーポレイション | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| AU2021380853B2 (en) * | 2020-12-23 | 2024-10-10 | Guangdong Feipeng Pharmaceutical Co., Ltd. | Antibody targeting CD47 and application thereof |
| US20240076412A1 (en) * | 2021-01-05 | 2024-03-07 | National Institute Of Biological Sciences, Beijing | A bispecific antibody targeting gpc3 and cd47 |
| KR20230129481A (ko) * | 2021-01-08 | 2023-09-08 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Cd47과 특이적으로 결합하는 항체 및 그 항원 결합단편 |
| BR112023016713A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954B2 (en) | 2021-10-29 | 2026-04-23 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| US20250304694A1 (en) * | 2022-06-29 | 2025-10-02 | Korea University Research And Business Foundation | Glycosylated fc variants of which binding affinity for human fcgrs is removed |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| JP2025522972A (ja) * | 2022-07-10 | 2025-07-17 | エムブレース セラピューティクス，インコーポレーテッド | 組換え抗体の無細胞産生の方法 |
| KR20250036855A (ko) | 2022-07-12 | 2025-03-14 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| JP2025540215A (ja) | 2022-12-09 | 2025-12-11 | ファイザー・インク | Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025179135A1 (en) * | 2024-02-23 | 2025-08-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer using targeted pore-forming agents |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026089992A1 (en) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO2001044301A1 (en) | 1999-11-29 | 2001-06-21 | Unilever Plc | Immobilized single domain antigen-binding molecules |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| KR101123487B1 (ko) | 2007-03-20 | 2012-03-23 | 일라이 릴리 앤드 캄파니 | 항?스클레로스틴 항체 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| JP2014519338A (ja) * | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | 治療薬として使用される可溶性タンパク質 |
| JP6460796B2 (ja) * | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｓｉｒｐ−アルファ試薬 |
| EA034778B1 (ru) | 2012-02-06 | 2020-03-19 | Инхибркс, Инк. | Антитела к cd47 и способы их применения |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| JP2016507555A (ja) * | 2013-02-06 | 2016-03-10 | インヒブルクス エルピー | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
| AU2014253785B2 (en) * | 2013-04-19 | 2018-07-19 | Sutro Biopharma, Inc. | Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones |
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| WO2017049251A2 (en) | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| HK1257309A1 (zh) | 2015-09-21 | 2019-10-18 | Erasmus University Medical Center | 抗-cd47抗体及使用方法 |
-
2015
- 2015-12-28 WO PCT/US2015/067642 patent/WO2016109415A1/en not_active Ceased
- 2015-12-28 EA EA201791485A patent/EA037654B1/ru unknown
- 2015-12-28 MX MX2017008819A patent/MX391051B/es unknown
- 2015-12-28 SG SG11201705310TA patent/SG11201705310TA/en unknown
- 2015-12-28 KR KR1020177021330A patent/KR102489471B1/ko active Active
- 2015-12-28 CN CN201580077136.5A patent/CN107530421B/zh not_active Expired - Fee Related
- 2015-12-28 HK HK18104961.7A patent/HK1245154A1/zh unknown
- 2015-12-28 EP EP15876093.4A patent/EP3240569A4/en not_active Withdrawn
- 2015-12-28 US US15/541,003 patent/US10870699B2/en active Active
- 2015-12-28 CA CA2972604A patent/CA2972604C/en active Active
- 2015-12-28 JP JP2017535814A patent/JP6850255B2/ja not_active Expired - Fee Related
- 2015-12-28 BR BR112017014258A patent/BR112017014258A2/pt not_active IP Right Cessation
- 2015-12-28 SG SG10202007176TA patent/SG10202007176TA/en unknown
- 2015-12-28 AU AU2015374301A patent/AU2015374301B2/en not_active Ceased
-
2017
- 2017-06-29 CL CL2017001736A patent/CL2017001736A1/es unknown
- 2017-06-30 EC ECIEPI201741865A patent/ECSP17041865A/es unknown
- 2017-06-30 ZA ZA2017/04467A patent/ZA201704467B/en unknown
- 2017-07-28 CO CONC2017/0007673A patent/CO2017007673A2/es unknown
-
2020
- 2020-10-29 US US16/949,459 patent/US11787860B2/en active Active
- 2020-12-01 JP JP2020199312A patent/JP2021048858A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2021524256A5 (enExample) | ||
| EP4050034A1 (en) | Cd3 binding antibodies | |
| AU2017281034A1 (en) | CD3 binding antibodies | |
| JP2013515508A5 (enExample) | ||
| TW202208429A (zh) | 用於治療多發性骨髓瘤之方法 | |
| JP2012526558A5 (enExample) | ||
| JP2022549172A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP2013519690A5 (enExample) | ||
| IL301330A (en) | CD47-CD38 bispecific antibodies | |
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| JP2023517660A5 (enExample) | ||
| AU2023353699A1 (en) | Multispecific antibodies and methods of use thereof | |
| WO2014072741A1 (en) | Humanised antibody and method of production thereof | |
| CA3029977A1 (en) | Antibodies with low immunogenicity and uses thereof | |
| AU2024362545A1 (en) | Sirp antibodies for treatment of hemophagocytic lymphohistiocytosis | |
| CN117120478A (zh) | 一种抗原结合分子 | |
| JP2023500701A5 (enExample) | ||
| JP2022521956A5 (enExample) | ||
| WO2025085857A1 (en) | Sirp antibodies for treatment of cancer | |
| CN116462764A (zh) | 靶向cd47和her2的多特异性抗体及其用途 | |
| WO2025226685A1 (en) | Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections | |
| US20240141062A1 (en) | Cd47-cd38 bispecific antibodies | |
| TW202608477A (zh) | 用於治療愛潑斯坦—巴爾病毒感染之ＳＩＲＰα、β、γ抗體 |